Image Source: www.biopharma-reporter.com 

ReNeuron will automate processing of its stem cell-based stroke therapy ahead of planned Phase III trials using a system acquired from Sartorius Stedim Biotech (SSB) subsidiary, TAP Biosystems.

Read the complete article by Gareth McDonald here: www.biopharma-reporter.com